2018 UK national guideline for the management of infection with Neisseria gonorrhoeae

Sherrard J and Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996; 72(6): 422–426.

Lewis DA Bond M Butt KD , et al. A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS 1999; 10(9): 588–94. doi: 10.1258/0956462991914717.

Barlow D and Phillips I. Gonorrhoea in women. Diagnostic, clinical, and laboratory aspects. Lancet 1978; 1(8067): 761–764.

Barry PM Kent CK Philip SS , et al. Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol 2010; 115(4): 753–759. doi: 10.1097/AOG.0b013e3181d444f6 [published Online First: 2010/03/24]..

Morris GC Stewart CM Schoeman SA , et al. A cross-sectional study showing differences in the clinical diagnosis of pelvic inflammatory disease according to the experience of clinicians: implications for training and audit. Sex Transm Infect 2014; 90(6): 445–451. doi: 10.1136/sextrans-2014-051646.

Hughes G Ison C Field N , et al. Guidance for the detection of gonorrhoea in England. In: Public Health England, ed. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/40 5293/170215_Gonorrhoea_testing_guidance_REVISED 2_.pdf, 2014.

Whiley DM Garland SM Harnett G , et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 2008; 5(1): 17–23.

Van Dyck E Ieven M Pattyn S , et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol 2001; 39(5): 1751–1756. doi: 10.1128/JCM.39.5.1751-1756.2001.

Cook RL Hutchison SL Ostergaard L , et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005; 142(11): 914–925.

Thorley N and Radcliffe K. The performance and clinical utility of cervical microscopy for the diagnosis of gonorrhoea in women in the era of the NAAT. Int J STD AIDS 2015; 26(9): 656–660. doi: 10.1177/0956462414551233.

Grover D Prime KP Prince MV , et al. Rectal gonorrhoea in men – is microscopy still a useful tool? International Journal of STD & AIDS 2006; 17(4): 277–279. doi: 10.1258/095646206776253363.

Forni J Miles K and Hamill M. Microscopy detection of rectal gonorrhoea in asymptomatic men. International journal of STD & AIDS 2009; 20(11): 797–798. doi: 10.1258/ijsa.2009.009186.

Levy V Blackmore CS and Klausner JD. Self-collection of specimens for nucleic acid-based diagnosis of pharyngeal, cervicovaginal, urethral, and rectal Neisseria gonorrhoeae and Chlamydia trachomatis infections. Methods Mol Biol 2012; 903: 407–418. doi: 10.1007/978-1-61779-937-2_28.

Gaydos CA Van Der Pol B Jett-Goheen M , et al. Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2013; 51(6): 1666–1672. doi: 10.1128/JCM.03461-12.

Cornelisse VJ Chow EP Huffam S , et al. Increased Detection of Pharyngeal and Rectal Gonorrhea in Men Who Have Sex With Men After Transition From Culture To Nucleic Acid Amplification Testing. Sex Transm Dis 2017; 44(2): 114–117. doi: 10.1097/OLQ.0000000000000553.

Van Der Pol B Hook EW 3rd Williams JA , et al. Performance of the BD CTQx and GCQx Amplified Assays on the BD Viper LT Compared With the BD Viper XTR System. Sex Transm Dis 2015; 42(9): 521–523. doi: 10.1097/OLQ.0000000000000313.

Geelen TH Rossen JW Beerens AM , et al. Performance of Cobas(R) 4800 and m2000 real-time assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis 2013; 77(2): 101–105. doi: 10.1016/j.diagmicrobio.2013.06.020.

Palmer HM Mallinson H Wood RL , et al. Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae. J Clin Microbiol 2003; 41(2): 835–837.

Pope CF Hay P Alexander S , et al. Positive predictive value of the Becton Dickinson VIPER system and the ProbeTec GC Q x assay, in extracted mode, for detection of Neisseria gonorrhoeae. Sex Transm Infect 2010; 86(6): 465–469. doi: 10.1136/sti.2010.044065.

Sultan B White JA Fish R , et al. The “3 in 1” Study: Pooling Self-Taken Pharyngeal, Urethral, and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men. J Clin Microbiol 2016; 54(3): 650–656. doi: 10.1128/JCM.02460-15.

Chernesky MA Martin DH Hook EW , et al. Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol 2005; 43(1): 127–131. doi: 10.1128/JCM.43.1.127-131.2005.

Schachter J Chernesky MA Willis DE , et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005; 32(12): 725–728.

Stewart CM Schoeman SA Booth RA , et al. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ 2012; 345: e8107. doi: 10.1136/bmj.e8107.

Van Der Pol B Taylor SN Liesenfeld O , et al. Vaginal swabs are the optimal specimen for detection of genital Chlamydia trachomatis or Neisseria gonorrhoeae using the Cobas 4800 CT/NG test. Sex Transm Dis 2013; 40(3): 247–250. doi: 10.1097/OLQ.0b013e3182717833.

Benn PD Rooney G Carder C , et al. Chlamydia trachomatis and Neisseria gonorrhoeae infection and the sexual behaviour of men who have sex with men. Sex Transm Infect 2007; 83(2): 106–112. doi: 10.1136/sti.2006.021329.

Lavelle SJ Jones KE Mallinson H , et al. Finding, confirming, and managing gonorrhoea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. Sex Transm Infect 2006; 82(3): 221–224. doi: 10.1136/sti.2005.017616.

Pond MJ Hall CL Miari VF , et al. Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy. J Antimicrob Chemother 2016; 71(4): 897–902. doi: 10.1093/jac/dkv432.

van Liere G Dukers-Muijrers N Levels L , et al. High Proportion of Anorectal Chlamydia trachomatis and Neisseria gonorrhoeae After Routine Universal Urogenital and Anorectal Screening in Women Visiting the Sexually Transmitted Infection Clinic. Clin Infect Dis 2017; 64(12): 1705–1710. doi: 10.1093/cid/cix243.

Jin F Prestage GP Kippax SC , et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007; 34(7): 488–493. doi: 10.1097/01.olq.0000245960.52668.e5.

van Liere GA Hoebe CJ Niekamp AM , et al. Standard symptom- and sexual history-based testing misses anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections in swingers and men who have sex with men. Sex Transm Dis 2013; 40(4): 285–289. doi: 10.1097/OLQ.0b013e31828098f8 [published Online First: 2013/03/15].

Moran JS and Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(Suppl 1): S47–S65.

Eyre DW Sanderson ND Lord E , et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018; 23(27). doi: 10.2807/1560-7917.ES.2018.23.27.1800323.

Fifer H Natarajan U Jones L , et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med 2016; 374(25): 2504–2506. doi: 10.1056/NEJMc1512757.

Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22(1): 39–47.

Chen SC Yin YP Dai XQ , et al. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China. J Antimicrob Chemother 2016; 71(1): 92–99. doi: 10.1093/jac/dkv321.

Peng T Lin H Liu Q , et al. Ceftriaxone susceptibility and molecular characteristics of Neisseria gonorrhoeae isolates in Changsha, China. J Infect Chemother 2017; 23(6): 385–389. doi: 10.1016/j.jiac.2017.03.007.

Chen Y Gong Y Yang T , et al. Antimicrobial resistance in Neisseria gonorrhoeae in China: a meta-analysis. BMC Infect Dis 2016; 16: 108. doi: 10.1186/s12879-016-1435-0.

Jiang FX Lan Q Le WJ , et al. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from Hefei (2014–2015): genetic characteristics of antimicrobial resistance. BMC Infect Dis 2017; 17(1): 366. doi: 10.1186/s12879-017-2472-z.

Fiumara NJ and Asvadi S. Asymptomatic gonococcal urethritis in a male transsexual female. Br J Vener Dis 1978; 54(2): 130–131.

van der Sluis WB Bouman MB Gijs L , et al. Gonorrhoea of the sigmoid neovagina in a male-to-female transgender. Int J STD AIDS 2015; 26(8): 595–598. doi: 10.1177/0956462414544725.

Bodsworth NJ Price R and Davies SC. Gonococcal infection of the neovagina in a male-to-female transsexual. Sex Transm Dis 1994; 21(4): 211–212.

Haustein UF. [ Pruritus of the artificial vagina of a transsexual patient caused by gonococcal infection]. Hautarzt 1995; 46(12): 858–859.

Public Health England. Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2017. 2018.

BASHH Clinical Effectiveness Group. BASHH CEG guidance on tests for Sexually Transmitted Infections. https://www.bashhguidelines.org/media/1084/sti-testing-tables-2015-dec-update-4.pdf, 2015.

FitzGerald M and Bedford C. National standards for the management of gonorrhoea. Int J STD AIDS 1996; 7(4): 298–300. doi: 10.1258/0956462961917861.

Echols RM Heyd A O'Keeffe BJ , et al. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex Transm Dis 1994; 21(6): 345–352.

Moran JS. Ciprofloxacin for gonorrhea–250 mg or 500 mg? Sex Transm Dis 1996; 23(2): 165–167.

Allan-Blitz LT Wang X and Klausner JD. Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. Sex Transm Dis 2017; 44(5): 261–265. doi: 10.1097/OLQ.0000000000000591.

Allan-Blitz LT Humphries RM Hemarajata P , et al. Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System. Clin Infect Dis 2017; 64(9): 1268–1270. doi: 10.1093/cid/ciw864 [published Online First: 2016/12/31].

Town K Obi C Quaye N , et al. Drifting towards ceftriaxone treatment failure in gonorrhoea: risk factor analysis of data from the Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales. Sex Transm Infect 2017; 93(1): 39–45. doi: 10.1136/sextrans-2016-052583.

Lefebvre B Martin I Demczuk W , et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis 2018; 24(2) doi: 10.3201/eid2402.171756.

Camara J Serra J Ayats J , et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012; 67(8): 1858–1860. doi: 10.1093/jac/dks162.

Unemo M Golparian D Nicholas R , et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56(3): 1273–1280. doi: 10.1128/AAC.05760-11.

Whiley DM Jennison A Pearson J , et al. Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. Lancet Infect Dis 2018; 18(7): 717–718. doi: 10.1016/S1473-3099(18)30340-2.

Lahra MM Martin I Demczuk W , et al. Cooperative Recognition of Internationally Disseminated Ceftriaxone- Resistant Neisseria gonorrhoeae Strain. Emerg Infect Dis 2018; 24(4). doi: 10.3201/eid2404.171873.

Chisholm SA Mouton JW Lewis DA , et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65(10): 2141–2148. doi: 10.1093/jac/dkq289.

Barbee LA Soge OO Holmes KK , et al. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother 2014; 69(6): 1572–1578. doi: 10.1093/jac/dkt540.

Pereira R Cole MJ and Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother 2013; 68(3): 640–643. doi: 10.1093/jac/dks449.

Wind CM de Vries HJ and van Dam AP. Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution. Int J Antimicrob Agents 2015; 45(3): 305–308. doi: 10.1016/j.ijantimicag.2014.10.020.

Furuya R Nakayama H Kanayama A , et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12(4): 172–176. doi: 10.1007/s10156-006-0445-z.

Singh V Bala M Bhargava A , et al. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One 2018; 13(3): e0193678. doi: 10.1371/journal.pone.0193678.

Cole MJ Spiteri G Jacobsson S , et al. Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015. BMC Infect Dis 2017; 17(1): 617. doi: 10.1186/s12879-017-2707-z.

Yasuda M Ito S Hatazaki K , et al. Remarkable increase of Neisseria gonorrhoeae with decreased susceptibility of azithromycin and increase in the failure of azithromycin therapy in male gonococcal urethritis in Sendai in 2015. J Infect Chemother 2016; 22(12): 841–843. doi: 10.1016/j.jiac.2016.07.012.

Wi T Lahra MM Ndowa F , et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med 2017; 14(7): e1002344. doi: 10.1371/journal.pmed.1002344.

Lahra MM Ward A Trembizki E , et al. Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis 2017; 17(2): 133–134. doi: 10.1016/S1473-3099(17)30007-5.

Wind CM Schim van der Loeff MF van Dam AP , et al. Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 and 2015. Euro Surveill 2017; 22(1). doi: 10.2807/1560-7917.ES.2017.22.1.30431.

Fifer H Cole M Hughes G , et al. Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study. Lancet Infect Dis 2018; 18(5): 573–581. doi: 10.1016/S1473- 3099(18)30122-1.

Katz AR Komeya AY Kirkcaldy RD , et al. Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016. Clin Infect Dis 2017; 65(6): 918–923. doi: 10.1093/cid/cix485.

Ross JD Harding J Duley L , et al. LB1.5 The efficacy and safety of gentamicin for the treatment of genital, pharyngeal and rectal gonorrhoea: a randomised controlled trial. Sexually Transmitted Infections 2017; 93(Suppl 2): A42–A43. doi: 10.1136/sextrans-2017-053264.106.

Handsfield HH Dalu ZA Martin DH , et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21(2): 107–111.

Zheng S Matzneller P Zeitlinger M , et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. Antimicrob Agents Chemother 2014; 58(11): 6675–6684. doi: 10.1128/AAC.02904-14.

Matzneller P Krasniqi S Kinzig M , et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 2013; 57(4): 1736–1742. doi: 10.1128/AAC.02011-12.

Crokaert F Hubloux A and Cauchie P. A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500 mg Once Daily for 3 Days. Clin Drug Investig 1998; 16(2): 161–166.

Buono SA Watson TD Borenstein LA , et al. Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother 2015; 70(2): 374–381. doi: 10.1093/jac/dku396 [published Online First: 2014/10/22].

European Medicines Agency. Review of Quinolone- and fluoroquinolone- containing medicinal products. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products2018 [accessed 10th January 2019].

Sathia L Ellis B Phillip S , et al. Pharyngeal gonorrhoea - is dual therapy the way forward? Int J STD AIDS 2007; 18(9): 647–648. doi: 10.1258/095646207781568556.

Barbee LA Kerani RP Dombrowski JC , et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56(11): 1539–1545. doi: 10.1093/cid/cit084.

Ison CA Hussey J Sankar KN , et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16(14).

Unemo M Golparian D Syversen G , et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15(47).

Pichichero ME and Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007; 136(3): 340–347. doi: 10.1016/j.otohns.2006.10.007.

Zagursky RJ and Pichichero ME. Cross-reactivity in beta-Lactam Allergy. The journal of allergy and clinical immunology In practice 2018; 6(1): 72–81.e1. doi: 10.1016/j.jaip.2017.08.027 [published Online First: 2017/10/12].

Kirkcaldy RD Weinstock HS Moore PC , et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59(8): 1083–1091. doi: 10.1093/cid/ciu521.

Tapsall JW Shultz TR Limnios EA , et al. Failure of Azithromycin Therapy in Gonorrhea and Discorrelation With Laboratory Test Parameters. Sexually Transmitted Diseases 1998; 25(10): 505–508.

Haimovici R and Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. American journal of ophthalmology 1989; 107(5): 511–514. [published Online First: 1989/05/15].

Brocklehurst P. Antibiotics for gonorrhoea in pregnancy. Cochrane Database Syst Rev 2002; (2): CD000098. doi: 10.1002/14651858.CD000098.

Cavenee MR Farris JR Spalding TR , et al. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993; 81(1): 33–38.

Ramus RM Sheffield JS Mayfield JA , et al. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. Am J Obstet Gynecol 2001; 185(3): 629–632. doi: 10.1067/mob.2001.117662.

FitzGerald M Thirlby D Bell G , et al. National standards for contact tracing in gonorrhoea. Royal College of Physicians, National Audit Development Programme in Sexual Health. Int J STD AIDS 1996; 7(4): 301. doi: 10.1258/0956462961917870.

McClean H Radcliffe K Sullivan A , et al. 2012 BASHH statement on partner notification for sexually transmissible infections. International Journal of STD & AIDS 2013; 24(4): 253–261. doi: 10.1177/0956462412472804.

Mensforth S and Radcliffe K. Is it time to reconsider epidemiological treatment for gonorrhoea? Int J STD AIDS 2018; 29(10): 1043–1044. doi: 10.1177/0956462418787611.

Jephcott AE. Microbiological diagnosis of gonorrhoea. Genitourin Med 1997; 73(4): 245–252.

Wind CM Schim van der Loeff MF Unemo M , et al. Test of Cure for Anogenital Gonorrhoea Using Modern RNA- Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study. Clin Infect Dis 2016; 262(11): 1348–1355. doi: 10.1093/cid/ciw141.